Reproductive Health · AdenomyosisTrial Updateclinicalmid-term

Linzagolix Evaluated for Adenomyosis and Recurrent Implantation Failure in New Study

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/14/2026, 6:04:16 AM

Assessment confidence: 54% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The evaluation of linzagolix for adenomyosis and recurrent implantation failure could significantly enhance treatment options in reproductive health. Success in this trial may lead to a shift in market dynamics for fertility treatments, necessitating close monitoring by pharma strategy teams. Regulatory context from MHRA (ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly) supports the near-term read. Assessment grounded in 20 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should monitor the outcomes of this trial as it may influence future product positioning and development strategies in reproductive health. The strongest clinical anchor is Linzagolix in Adenomyosis and Recurrent Implantation Failure (ClinicalTrials.gov), entity match (linzagolix); patient population match (recurrent). In Reproductive Health · Adenomyosis, 4 regulatory and 2 competitive items passed relevance filtering for Linzagolix.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility. If successful, linzagolix could enhance treatment options for patients with adenomyosis, potentially impacting the market for fertility treatments.

Regulatory Outlook

Regulatory risk is concentrated around ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly (MHRA). Regulatory pathway relevance (nda). Relevant agencies in corpus: MHRA, FDA. The outcomes of this trial may inform future regulatory submissions and labeling for linzagolix, impacting its positioning in the market for reproductive health therapies.

Key Risks

Elevated medium regulatory exposure for Linzagolix could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If linzagolix demonstrates improved live birth rates, it could capture a notable share of the fertility treatment market, influencing revenue streams for companies involved in reproductive health.
Portfolio teams should monitor the outcomes of this trial as it may influence future product positioning and development strategies in reproductive health.

What Would Change This Assessment

This becomes more urgent if Key milestones include the primary endpoint results on live birth rates and secondary outcomes related to pregnancy rates and tolerability.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
MHRAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Psychedelic Drugs
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots: YARTEMLEA
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots: PALSONIFY
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Linzagolix in Adenomyosis and Recurrent Implantation Failure
ClinicalTrials.govhigh relevance
Entity match (linzagolix); Patient population match (recurrent)
FDA document
View source
A Study of LY4178256 in Healthy Participants
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Lilly)
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial of Treatments for COVID-19 in Hospitalized Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Reducing Disparities in Behavioral Health Treatment for Children in Primary Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Linzagolix
fertility treatment market

Commercial impact

medium

If linzagolix demonstrates improved live birth rates, it could capture a notable share of the fertility treatment market, influencing revenue streams for companies involved in reproductive health.

Regulatory impact

medium

The outcomes of this trial may inform future regulatory submissions and labeling for linzagolix, impacting its positioning in the market for reproductive health therapies.

What to watch

Key milestones include the primary endpoint results on live birth rates and secondary outcomes related to pregnancy rates and tolerability.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.